Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 3Breast 2Thoracic 1Sarcoma 1Head & Neck 1Genitourinary 1Gastrointestinal 1

Conditions

Colorectal Neoplasms 3Head and Neck Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Uterine Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Kidney Neoplasms 1Gallbladder Neoplasms 1Fibromatosis, Gingival, 2 1Esophageal Neoplasms 1Cholangiocarcinoma 1Breast Neoplasms 1Bile Duct Neoplasms 1

Interventions

pembrolizumab 28Nivolumab 13Carboplatin 9fludarabine 7Paclitaxel 7Gemcitabine 7Docetaxel 7Cyclophosphamide 7Cisplatin 7Trastuzumab 5palbociclib 4cemiplimab 4avelumab 4atezolizumab 4Ipilimumab 4Fluorouracil 4Filgrastim 4Drug Therapy 4Cetuximab 4fludarabine phosphate 3epacadostat 3durvalumab 3Taxes 3Oxaliplatin 3Fulvestrant 3zimberelimab 2ulixertinib 2trametinib 2tisotumab vedotin 2spartalizumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ovarian Neoplasms × seribantumab × Head & Neck × Clear all
NCT04383210 2025-04-03

Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors

Elevation Oncology

Phase 2 Terminated
54 enrolled 11 charts
BreastGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Fibromatosis, Gingival, 2, Bile Duct Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Uterine Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡